Prestige Consumer Healthcare Stock Forecast, Price & News

+0.14 (+0.27 %)
(As of 07/28/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume134,016 shs
Average Volume397,723 shs
Market Capitalization$2.64 billion
P/E Ratio16.25
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive PBH News and Ratings via Email

Sign-up to receive the latest news and ratings for Prestige Consumer Healthcare and its competitors with MarketBeat's FREE daily newsletter.

Prestige Consumer Healthcare logo

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) healthcare products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye allergies/redness relief, Compound W wart removals, Debrox ear wax removals, DenTek for PEG oral care, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.75 out of 5 stars

Consumer Discretionary Sector

202nd out of 615 stocks

Pharmaceutical Preparations Industry

322nd out of 867 stocks

Analyst Opinion: 3.3Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Prestige Consumer Healthcare (NYSE:PBH) Frequently Asked Questions

Is Prestige Consumer Healthcare a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Prestige Consumer Healthcare in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Prestige Consumer Healthcare stock.
View analyst ratings for Prestige Consumer Healthcare
or view top-rated stocks.

What stocks does MarketBeat like better than Prestige Consumer Healthcare?

Wall Street analysts have given Prestige Consumer Healthcare a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Prestige Consumer Healthcare wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Prestige Consumer Healthcare's next earnings date?

Prestige Consumer Healthcare is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Prestige Consumer Healthcare

How can I listen to Prestige Consumer Healthcare's earnings call?

Prestige Consumer Healthcare will be holding an earnings conference call on Thursday, August 5th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 404-537-3406 with passcode "5362477".

How were Prestige Consumer Healthcare's earnings last quarter?

Prestige Consumer Healthcare Inc. (NYSE:PBH) announced its quarterly earnings results on Thursday, May, 6th. The company reported $0.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.78 by $0.01. The firm earned $237.80 million during the quarter, compared to the consensus estimate of $230.59 million. Prestige Consumer Healthcare had a trailing twelve-month return on equity of 12.65% and a net margin of 17.46%. Prestige Consumer Healthcare's quarterly revenue was down 5.3% on a year-over-year basis. During the same period last year, the company posted $0.82 earnings per share.
View Prestige Consumer Healthcare's earnings history

How has Prestige Consumer Healthcare's stock price been impacted by COVID-19?

Prestige Consumer Healthcare's stock was trading at $35.91 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PBH shares have increased by 47.1% and is now trading at $52.81.
View which stocks have been most impacted by COVID-19

What guidance has Prestige Consumer Healthcare issued on next quarter's earnings?

Prestige Consumer Healthcare issued an update on its FY 2022 earnings guidance on Thursday, May, 27th. The company provided earnings per share (EPS) guidance of 3.580- for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.420. The company issued revenue guidance of $957 million-$962 million, compared to the consensus revenue estimate of $949.31 million.

What price target have analysts set for PBH?

4 equities research analysts have issued 12-month target prices for Prestige Consumer Healthcare's stock. Their forecasts range from $52.00 to $125.00. On average, they anticipate Prestige Consumer Healthcare's share price to reach $101.25 in the next year. This suggests a possible upside of 91.7% from the stock's current price.
View analysts' price targets for Prestige Consumer Healthcare
or view top-rated stocks among Wall Street analysts.

Who are Prestige Consumer Healthcare's key executives?

Prestige Consumer Healthcare's management team includes the following people:
  • Mr. Ronald M. Lombardi, Chairman, Pres & CEO (Age 57, Pay $1.98M)
  • Ms. Christine Sacco, Chief Financial Officer (Age 45, Pay $930.5k)
  • Mr. Jeffrey Zerillo, Sr. VP of Operations (Age 60, Pay $480.41k)
  • Mr. William C. P'Pool, Sr. VP, Gen. Counsel & Corp. Sec. (Age 56, Pay $735.71k)
  • Mr. Adel Mekhail, Exec. VP of Marketing & Sales (Age 60, Pay $679.38k)
  • Mr. Philip David Terpolilli, Director of Investor Relations
  • Dean Siegal, Director of Communications
  • Ms. Mary Beth Fritz, Sr. VP of Quality & Regulatory Affairs

What is Ronald M. Lombardi's approval rating as Prestige Consumer Healthcare's CEO?

8 employees have rated Prestige Consumer Healthcare CEO Ronald M. Lombardi on Glassdoor.com. Ronald M. Lombardi has an approval rating of 61% among Prestige Consumer Healthcare's employees. This puts Ronald M. Lombardi in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Prestige Consumer Healthcare's key competitors?

What other stocks do shareholders of Prestige Consumer Healthcare own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prestige Consumer Healthcare investors own include Pfizer (PFE), AbbVie (ABBV), Gilead Sciences (GILD), AT&T (T), Intel (INTC), ONEOK (OKE), Wells Fargo & Company (WFC), International Business Machines (IBM), Micron Technology (MU) and Teva Pharmaceutical Industries (TEVA).

What is Prestige Consumer Healthcare's stock symbol?

Prestige Consumer Healthcare trades on the New York Stock Exchange (NYSE) under the ticker symbol "PBH."

Who are Prestige Consumer Healthcare's major shareholders?

Prestige Consumer Healthcare's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include State of Alaska Department of Revenue (0.07%), Oregon Public Employees Retirement Fund (0.04%), 6 Meridian (0.02%) and CHICAGO TRUST Co NA (0.01%). Company insiders that own Prestige Consumer Healthcare stock include Mary Beth Fritz, Paton Brett and Ronald M Lombardi.
View institutional ownership trends for Prestige Consumer Healthcare

Which major investors are selling Prestige Consumer Healthcare stock?

PBH stock was sold by a variety of institutional investors in the last quarter, including Oregon Public Employees Retirement Fund, and 6 Meridian.
View insider buying and selling activity for Prestige Consumer Healthcare
or view top insider-selling stocks.

Which major investors are buying Prestige Consumer Healthcare stock?

PBH stock was acquired by a variety of institutional investors in the last quarter, including CHICAGO TRUST Co NA, and State of Alaska Department of Revenue.
View insider buying and selling activity for Prestige Consumer Healthcare
or or view top insider-buying stocks.

How do I buy shares of Prestige Consumer Healthcare?

Shares of PBH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Prestige Consumer Healthcare's stock price today?

One share of PBH stock can currently be purchased for approximately $52.81.

How much money does Prestige Consumer Healthcare make?

Prestige Consumer Healthcare has a market capitalization of $2.64 billion and generates $943.36 million in revenue each year. The company earns $164.68 million in net income (profit) each year or $3.24 on an earnings per share basis.

How many employees does Prestige Consumer Healthcare have?

Prestige Consumer Healthcare employs 505 workers across the globe.

What is Prestige Consumer Healthcare's official website?

The official website for Prestige Consumer Healthcare is www.prestigebrands.com.

Where are Prestige Consumer Healthcare's headquarters?

Prestige Consumer Healthcare is headquartered at 660 WHITE PLAINS ROAD SUITE 250, TARRYTOWN NY, 10591.

How can I contact Prestige Consumer Healthcare?

Prestige Consumer Healthcare's mailing address is 660 WHITE PLAINS ROAD SUITE 250, TARRYTOWN NY, 10591. The company can be reached via phone at 914-524-6800 or via email at [email protected]

This page was last updated on 7/29/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.